NIH says anti-allergy vaccine supply to resume next week

The National Institute of Health (NIH) has announced that the ongoing shortage of the anti-allergy vaccine will be resolved soon, with regular supply set to resume from December 3.

According to NIH sources, the temporary crisis occurred due to a delay in the availability of phenol, a key ingredient required for vaccine preparation.

Officials explained that ensuring the supply of phenol took longer than expected, which slowed down the production process. “The vaccine goes through various stages during preparation,” NIH stated, emphasizing that each batch must undergo an experimental testing period of 10 to 15 days. This rigorous process is designed to ensure patient safety and prevent any adverse reactions.

Phenol became available last week, and the testing phase for the newly prepared vaccine batches is currently underway. NIH expressed confidence that the vaccine crisis will be fully overcome within a week.

In the meantime, NIH has advised citizens to visit the institute after one week, once the vaccine is ready for safe administration.

The announcement brings relief to patients awaiting treatment, reaffirming NIH’s commitment to quality, safety, and timely healthcare delivery.